Targeted delivery of nano-PTX to the brain tumor-associated macrophages

Oncotarget

Volumn 8, Issue 4, 2017, Pages 6564-6578

  Zou, Lei ^a   Tao, Youhua ^a   Payne, Gregory ^a   Do, Linh ^a   Thomas, Tima ^a   Rodriguez, Juan ^a   Dou, Huanyu ^a,b  

^a Texas Tech University Health Sciences Center El Paso   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Brain targeted delivery; Glioma; Nanoparticles; Tumor associated macrophages

Indexed keywords

GLYCOPROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; NANOPARTICLE; PACLITAXEL; POLYGLACTIN; RABIES VIRUS GLYCOPROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; LACTIC ACID; LIGAND; LIPID; PEPTIDE FRAGMENT; POLYGLYCOLIC ACID; RABIES VIRUS GLYCOPROTEIN PEPTIDE; VIRAL PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ATOMIC FORCE MICROSCOPY; BLOOD BRAIN BARRIER; CANCER GROWTH; CELL VIABILITY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG RELEASE; DRUG UPTAKE; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IC50; LIPID MONOLAYER; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; MTT ASSAY; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PROTEIN EXPRESSION; SPHERICAL SHAPE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT, MASS AND SIZE; ANIMAL; BAGG ALBINO MOUSE; BRAIN TUMOR; CAPILLARY PERMEABILITY; CHEMISTRY; COCULTURE; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; DRUG SCREENING; HUMAN; MACROPHAGE; METABOLISM; NERVE CELL; PATHOLOGY; SCID MOUSE; TIME FACTOR; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DESIGN; GLIOMA; GLYCOPROTEINS; HUMANS; LACTIC ACID; LIGANDS; LIPIDS; MACROPHAGES; MALE; MICE, INBRED BALB C; MICE, SCID; NANOPARTICLES; NEURONS; PACLITAXEL; PEPTIDE FRAGMENTS; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; TIME FACTORS; TISSUE DISTRIBUTION; VIRAL PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85010711787     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.14169     Document Type: Article

References (61)

1. Guo J, Gao X, Su L, Xia H, Gu G, Pang Z, Jiang X, Yao L, Chen J, Chen H. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials. 2011; 32:8010-8020.
2. Lin CL, Lieu AS, Lee KS, Yang YHC, Kuo TH, Hung MH, Loh JK, Yen CP, Chang CZ, Howng SL, Hwang SL. The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme. Surgical Neurology. 2003; 60:402-406.
3. Burton EC, Lamborn KR, Feuerstein BG, Prados M, Scott J, Forsyth P, Passe S, Jenkins RB, Aldape KD. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer research. 2002; 62:6205-6210.
4. Liu W, Sood R, Chen Q, Sakoglu U, Hendren J, Cetin O, Miyake M, Liu KJ. Normobaric hyperoxia inhibits NADPH oxidase-mediated matrix metalloproteinase-9 induction in cerebral microvessels in experimental stroke. Journal of neurochemistry. 2008; 107:1196-1205.
5. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D, Hadani M, Ram Z. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg. 2004; 100:472-479.
6. Grahn AY, Bankiewicz KS, Dugich-Djordjevic M, Bringas JR, Hadaczek P, Johnson GA, Eastman S, Luz M. Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. Journal of neuro-oncology. 2009; 95:185-197.
7. Bernal GM, LaRiviere MJ, Mansour N, Pytel P, Cahill KE, Voce DJ, Kang S, Spretz R, Welp U, Noriega SE, Nunez L, Larsen G, Weichselbaum RR, Yamini B. Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma. Nanomedicine. 2014; 10:149-157.
8. William WN, Jr., Heymach JV, Kim ES, Lippman SM. Molecular targets for cancer chemoprevention. Nature reviews Drug discovery. 2009; 8:213-225.
9. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proceedings of the National Academy of Sciences. 2006; 103:6315-6320.
10. Liu Y, Huang R, Han L, Ke W, Shao K, Ye L, Lou J, Jiang C. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials. 2009; 30:4195-4202.
11. Tao Y, Han J, Dou H. Brain-targeting gene delivery using a rabies virus glycoprotein peptide modulated hollow liposome: bio-behavioral study. Journal of Materials Chemistry. 2012; 11808-11815.
12. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, Lee SK, Shankar P, Manjunath N. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 2007; 448:39-43.
13. Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, Ehrhart J, Silver AA, Sanberg PR, Tan J. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. Journal of neurochemistry. 2004; 89:337-343.
14. Kim SS, Ye C, Kumar P, Chiu I, Subramanya S, Wu H, Shankar P, Manjunath N. Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther. 18:993-1001.
15. Kennedy BC, Maier LM, D'Amico R, Mandigo CE, Fontana EJ, Waziri A, Assanah MC, Canoll P, Anderson RC, Anderson DE and Bruce JN. Dynamics of central and peripheral immunomodulation in a murine glioma model. BMC Immunol. 2009; 10:11.
16. Zhang L, Handel MV, Schartner JM, Hagar A, Allen G, Curet M, Badie B. Regulation of IL-10 expression by upstream stimulating factor (USF-1) in glioma-associated microglia. J Neuroimmunol. 2007; 184:188-197.
17. Nagai T, Tanaka M, Tsuneyoshi Y, Xu B, Michie SA, Hasui K, Hirano H, Arita K, Matsuyama T. Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta. Cancer Immunol Immunother. 2009; 58:1577-1586.
18. Dziurzynski K, Wei J, Qiao W, Hatiboglu MA, Kong LY, Wu A, Wang Y, Cahill D, Levine N, Prabhu S, Rao G, Sawaya R, Heimberger AB. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res. 17:4642-4649.
19. Ye XZ, Xu SL, Xin YH, Yu SC, Ping YF, Chen L, Xiao HL, Wang B, Yi L, Wang QL, Jiang XF, Yang L, Zhang P, Qian C, Cui YH, Zhang X, et al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-beta1 signaling pathway. J Immunol. 189:444-453.
20. Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, Sawaya R, Heimberger AB. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 12:1113-1125.
21. Hirano H, Tanioka K, Yokoyama S, Akiyama S, Kuratsu J. Angiogenic effect of thymidine phosphorylase on macrophages in glioblastoma multiforme. J Neurosurg. 2001; 95:89-95.
22. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature reviews Drug discovery. 2005; 4:145-160.
23. Xiong J, Meng F, Wang C, Cheng R, Liu Z, Zhong Z. Folate-conjugated crosslinked biodegradable micelles for receptor-mediated delivery of paclitaxel. Journal of Materials Chemistry. 2011; 21:5786-5794.
24. Harmon AM, Lash MH, Sparks SM, Uhrich KE. Preferential cellular uptake of amphiphilic macromolecule-lipid complexes with enhanced stability and biocompatibility. Journal of controlled release. 2011; 153:233-239.
25. Bilensoy E, Gurkaynak O, Dogan AL, Hincal AA. Safety and efficacy of amphiphilic beta-cyclodextrin nanoparticles for paclitaxel delivery. International journal of pharmaceutics. 2008; 347:163-170.
26. Chan JM, Zhang L, Yuet KP, Liao G, Rhee JW, Langer R, Farokhzad OC. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials. 2009; 30:1627-1634.
27. Liu Y, Li K, Pan J, Liu B, Feng SS. Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials. 2010; 31:330-338.
28. Ling G, Zhang P, Zhang W, Sun J, Meng X, Qin Y, Deng Y, He Z. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. Journal of controlled release. 2010; 148:241-248.
29. Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, Kingsley J, Gorantla S, Poluektova L, Nelson JA, Chaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood. 2006; 108:2827-2835.
30. Dou H, Morehead J, Destache CJ, Kingsley JD, Shlyakhtenko L, Zhou Y, Chaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology. 2007; 358:148-158.
31. Dou H, Grotepas CB, McMillan JM, Destache CJ, Chaubal M, Werling J, Kipp J, Rabinow B, Gendelman HE. Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS. The Journal of Immunology. 2009; 183:661-669.
32. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, Weisz A, de Lera AR, Gronemeyer H, Altucci L. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature medicine. 2005; 11:77-84.
33. Zhang L, Chan JM, Gu FX, Rhee JW, Wang AZ, Radovic-Moreno AF, Alexis F, Langer R, Farokhzad OC. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS nano. 2008; 2:1696-1702.
34. Chan JM, Zhang L, Tong R, Ghosh D, Gao W, Liao G, Yuet KP, Gray D, Rhee J-W, Cheng J, Golomb G, Libby P, Langer R, Farokhzad OC. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proceedings of the National Academy of Sciences. 2010; 107:2213-2218.
35. Ravazzolo E, Salmaso S, Mastrotto F, Bersani S, Gallon E, Caliceti P. pH-responsive lipid core micelles for tumour targeting. European Journal of Pharmaceutics and Biopharmaceutics. 2013; 83:346-357.
36. Song XR, Zheng Y, He G, Yang L, Luo YF, He ZY, Li SZ, Li JM, Yu S, Luo X, Hou SX, Wei YQ. Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma. Journal of pharmaceutical sciences. 2010; 99:4874-4879.
37. Chung YI, Kim JC, Kim YH, Tae G, Lee SY, Kim K, Kwon IC. The effect of surface functionalization of PLGA nanoparticles by heparin-or chitosan-conjugated Pluronic on tumor targeting. Journal of controlled release. 2010; 143:374-382.
38. Das M, Sahoo SK. Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy. Acta biomaterialia. 2011; 7:355-369.
39. Romero G, Estrela-Lopis I, Zhou J, Rojas E, Franco A, Espinel CS, Fernández AGl, Gao C, Donath E, Moya SE. Surface Engineered Poly(lactide-co-glycolide) Nanoparticles for Intracellular Delivery: Uptake and Cytotoxicity-A Confocal Raman Microscopic Study. Biomacromolecules. 2010; 11:2993-2999.
40. Wang Z, Ho PC. Self-assembled core-shell vascular-targeted nanocapsules for temporal antivasculature and anticancer activities. Small. 2010; 6:2576-2583.
41. Schädlich A, Caysa H, Mueller T, Tenambergen F, Rose C, Göpferich A, Kuntsche J, Mäder K. Tumor Accumulation of NIR Fluorescent PEG-PLA Nanoparticles: Impact of Particle Size and Human Xenograft Tumor Model. ACS nano. 2011; 5:8710-8720.
42. Fanciullino R, Mollard S, Giacometti S, Berda-Haddad Y, Chefrour M, Aubert C, Iliadis A, Ciccolini J. In Vitro and In Vivo Evaluation of Lipofufol, a New Triple Stealth Liposomal Formulation of Modulated 5-Fu: Impact on Efficacy and Toxicity. Pharm Res. 2013; 30:1281-1290.
43. Hu F, a Dzaye OD, Hahn A, Yu Y, Scavetta RJ, Dittmar G, Kaczmarek AK, Dunning KR, Ricciardelli C, Rinnenthal JL, Heppner FL, Lehnardt S, Synowitz M, Wolf SA, Kettenmann H. Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling. Neuro Oncol. 2015; 17:200-210.
44. Das G, Shiras A, Shanmuganandam K, Shastry P. Rictor regulates MMP-9 activity and invasion through Raf-1-MEK-ERK signaling pathway in glioma cells. Molecular carcinogenesis. 2011; 50:412-423.
45. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, Setty M, Leslie CS, Oei Y, Pedraza A, Zhang J, Brennan CW, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nature medicine. 2013; 19:1264-1272.
46. Ye XZ, Xu SL, Xin YH, Yu SC, Ping YF, Chen L, Xiao HL, Wang B, Yi L, Wang QL, Jiang XF, Yang L, Zhang P, Qian C, Cui YH, Zhang X, et al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-beta1 signaling pathway. J Immunol. 2012; 189:444-453.
47. Kumar Naraharisetti P, Yung Sheng Ong B, Wei Xie J, Kam Yiu Lee T, Wang CH, Sahinidis NV. In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma. Biomaterials. 2007; 28:886-894.
48. Montemor JP, Peria FM, Monti CR, Petrilli LS, Colli BO and Carlotti Junior CG. Concurrent chemoradiotherapy with weekly paclitaxel in malignant cerebral glioma treatment. Onkologie. 2008; 31:435-439.
49. Elkharraz K, Faisant N, Guse C, Siepmann F, Arica-Yegin B, Oger JM, Gust R, Goepferich A, Benoit JP, Siepmann J. Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: preparation and physicochemical characterization. International journal of pharmaceutics. 2006; 314:127-136.
50. Rice A, Liu Y, Michaelis ML, Himes RH, Georg GI, Audus KL. Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ. Journal of medicinal chemistry. 2005; 48:832-838.
51. Buxton DB. Nanomedicine for the management of lung and blood diseases. Nanomedicine (Lond). 2009; 4:331-339.
52. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 29:341-345.
53. Ye C, Abraham S, Wu H, Shankar P, Manjunath N. Silencing early viral replication in macrophages and dendritic cells effectively suppresses flavivirus encephalitis. PLoS One. 6:e17889.
54. Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. Journal of controlled release. 2012; 161:264-273.
55. Liu L, Guo K, Lu J, Venkatraman SS, Luo D, Ng KC, Ling EA, Moochhala S, Yang YY. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials. 2008; 29:1509-1517.
56. Zou L, Macias Sustaita A, Thomas T, Do L, Rodriguez J, Dou H. Size Effects of Nanocomplex on Tumor Associated Macrophages Targeted Delivery for Glioma. Journal of Nanomedicine & Nanotechnology. 2015; 6: 1-10.
57. Chen X, Zhang L, Zhang IY, Liang J, Wang H, Ouyang M, Wu S, da Fonseca AC, Weng L, Yamamoto Y, Yamamoto H, Natarajan R, Badie B. RAGE expression in tumor-associated macrophages promotes angiogenesis in glioma. Cancer research. 2014; 74:7285-7297.
58. Kennedy BC, Showers CR, Anderson DE, Anderson L, Canoll P, Bruce JN, Anderson RC. Tumor-associated macrophages in glioma: friend or foe? Journal of oncology. 2013; 2013:486912.
59. Perri SR, Nalbantoglu J, Annabi B, Koty Z, Lejeune L, Francois M, Di Falco MR, Beliveau R, Galipeau J. Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. Cancer research. 2005; 65:8359-8365.
60. Sousa S, Auriola S, Monkkonen J, Maatta J. Liposome encapsulated zoledronate favours M1-like behaviour in murine macrophages cultured with soluble factors from breast cancer cells. BMC cancer. 2015; 15:4.
61. Pal R, Chakraborty B, Nath A, Singh LM, Ali M, Rahman DS, Ghosh SK, Basu A, Bhattacharya S, Baral R, Sengupta M. Noble metal nanoparticle-induced oxidative stress modulates tumor associated macrophages (TAMs) from an M2 to M1 phenotype: An in vitro approach. International immunopharmacology. 2016; 38:332-341.